8,655 results match your criteria Alcoholic Hepatitis


The future of therapy for alcoholic hepatitis - Beyond corticosteroids.

J Hepatol 2019 Feb 18. Epub 2019 Feb 18.

Department of Hepatology, Imperial College, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.01.016DOI Listing
February 2019

Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment.

Cancer Med 2019 Feb 21. Epub 2019 Feb 21.

Hatano Red Cross Hospital, Kanagawa, Japan.

Background: It is well known that the incidence of developing hepatocelluler carcinoma (HCC) is increased in liver cirrhosis of different etiologies. However, comparison of HCC incidence in various liver diseases has not yet been estimated. We surveyed this comparison. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.1998DOI Listing
February 2019

Association between the concurrence of pre-existing chronic liver disease and worse prognosis in patients with an herb- thunb. induced liver injury: a case-control study from a specialised liver disease center in China.

BMJ Open 2019 Jan 15;9(1):e023567. Epub 2019 Jan 15.

Institute of Chinese Herbal Medicine, Beijing 302 Hospital, Beijing, China.

Objectives: The present study aimed to evaluate the association between the concurrence of pre-existing chronic liver diseases (CLD) and worse prognosis in patients with HILI.

Design: A case-control study.

Setting: Tertiary hospital specialising in liver diseases in China. Read More

View Article

Download full-text PDF

Source
http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2018-02356
Publisher Site
http://dx.doi.org/10.1136/bmjopen-2018-023567DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340630PMC
January 2019
1 Read

Iron and liver fibrosis: Mechanistic and clinical aspects.

World J Gastroenterol 2019 Feb;25(5):521-538

Department of Nutritional Sciences, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London SE1 9NH, United Kingdom.

Liver fibrosis is characterised by excessive deposition of extracellular matrix that interrupts normal liver functionality. It is a pathological stage in several untreated chronic liver diseases such as the iron overload syndrome hereditary haemochromatosis, viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and diabetes. Interestingly, regardless of the aetiology, iron-loading is frequently observed in chronic liver diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v25.i5.521DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371002PMC
February 2019

Evaluation of Relationship between Occurrence of Liver Cancer and Methylation of Fragile Histidine Triad (FHIT) and P16 Genes.

Med Sci Monit 2019 Feb 18;25:1301-1306. Epub 2019 Feb 18.

Department of Hepatobiliary Surgery, Third Central Hospital of Tianjin (Tianjin Institute of Hepatobiliary Disease, Tianjin Key Laboratory of Artificial Cell, Artificial Cell Engineering Technology Research Center of Public Health Ministry), Tianjin, China (mainland).

BACKGROUND We examined the level of fragile histidine triad (FHIT) and p16 gene methylation in patients with hepatocellular carcinoma and explored the relationship to liver cancer. MATERIAL AND METHODS There were 56 patients with primary liver cancer who were admitted to the hospital from July 2015 to October 2017 included in the liver cancer group, and 24 non-hepatoma patients (hepatitis A/hepatitis B/hepatitis C, liver cirrhosis, liver fibrosis, and fatty liver, alcoholic liver identified as a control group. Fasting venous blood samples were collected from the 2 groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/MSM.912315DOI Listing
February 2019

Good outcome of living donor liver transplantation for severe alcoholic hepatitis not responding to medical management: A single center experience of 39 patients.

Alcohol 2018 Jul 24;77:27-30. Epub 2018 Jul 24.

Medanta Institute of Liver Transplantation and Regenerative Medicine, Medanta The Medicity, Gurgaon, Delhi (NCR), India.

Introduction: There are limited data on outcomes of living donor liver transplantation (LDLT) for patients with severe alcoholic hepatitis.

Methods: The study included LDLT recipients for severe alcoholic hepatitis (n = 39) who did not improve with medical treatment and compared their outcomes with patients who underwent LDLT for alcoholic liver disease (n = 461). The diagnosis of severe alcoholic hepatitis was based on both clinical and explants data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.alcohol.2018.07.009DOI Listing

Gut microbiota in liver disease: Too much is harmful, nothing at all is not helpful either.

Am J Physiol Gastrointest Liver Physiol 2019 Feb 15. Epub 2019 Feb 15.

Medicine, UCSD, United States.

The intestinal microbiome plays an major role in the pathogenesis of liver disease, with a hallmark event being dysbiosis, or an imbalance of pathobionts and beneficial bacteria with the associated deleterious effects on its host. Reducing the number of intestinal bacteria with antibiotic treatment is generally advantageous in experimental liver diseases. Complete absence of intestinal microbiota as in germ-free rodents can be protective in autoimmune hepatitis, and hepatic tumors induced by chemicals; or it can exacerbate disease as in acute toxic liver injury and liver fibrosis/cirrhosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajpgi.00370.2018DOI Listing
February 2019
1 Read

as a Possible Risk Factor in the Development/Severity of Acute Alcoholic Hepatitis.

Hepatol Commun 2019 Feb 14;3(2):293-304. Epub 2018 Dec 14.

Department of Medicine University of Louisville Louisville KY.

Bacterial infection is frequently observed in patients with alcoholic liver disease (ALD). We examined a possible role of in the development/progression and severity of disease in patients with acute alcoholic hepatitis (AAH). Plasma specimens from 47 patients with AAH (16 moderate, Model for End-Stage Liver Disease [MELD] score <20]; 31 severe, MELD score >20) and 22 healthy controls (HCs) were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep4.1296DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357836PMC
February 2019

The Changing Face of Hepatocellular Carcinoma: Forecasting Prevalence of Nonalcoholic Steatohepatitis and Hepatitis C Cirrhosis.

J Clin Exp Hepatol 2019 Jan-Feb;9(1):50-55. Epub 2018 Feb 16.

Rush University Medical Center, 1653 W Congress Parkway, Chicago, IL 60612, USA.

Background/objectives: The purpose of this research is to analyze the past and forecast the future prevalence of Hepatitis C Virus (HCV) and Nonalcoholic Steatohepatitis (NASH) and their respective contribution to Hepatocellular Carcinoma (HCC) incidence in the setting of novel anti-viral agents and rising obesity rates in the United States.

Methods: Existing data of HCV and NASH prevalence in the United States utilizing the National Health and Nutrition Examination Survey (NHANES) and Organ Procurement and Transplantation Network (OPTN) was collected and analyzed to project future prevalence trends.

Results: Prevalence of NASH and HCV are expected to increase and decline respectively over the next two decades with alcoholic cirrhosis expected to stay relatively unchanged. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jceh.2018.02.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363953PMC
February 2018
1 Read

Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD) as Serological Fibrosis Marker.

J Clin Exp Hepatol 2019 Jan-Feb;9(1):29-33. Epub 2018 Feb 16.

Department of Gastroenterology, Faculty of Medicine, Gazi University, Ankara, Turkey.

Background/aims: Progressive hepatic fibrosis is the main predictor of outcome and prognosis in chronic liver diseases. The importance of the coagulation cascade has been defined in liver fibrosis; however, the role of the fibrinolytic pathway has not been clear yet. We aimed to evaluate the association between the plasma levels of soluble urokinase Plasminogen Activator Receptor (uPAR) and the severity of liver fibrosis in chronic hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jceh.2018.02.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363952PMC
February 2018
1 Read

Controlled Attenuation Parameter for Assessment of Hepatic Steatosis in Indian Patients.

J Clin Exp Hepatol 2019 Jan-Feb;9(1):13-21. Epub 2018 Mar 14.

Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.

Background/aims: The gold standard method for measurement of hepatic steatosis is liver histology. Controlled Attenuation Parameter (CAP) can measure hepatic steatosis non-invasively. We aimed to assess the accuracy of CAP for detection of hepatic steatosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jceh.2018.02.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363949PMC
March 2018
1 Read

Review article: iron disturbances in chronic liver diseases other than haemochromatosis - pathogenic, prognostic, and therapeutic implications.

Authors:
Albert J Czaja

Aliment Pharmacol Ther 2019 Feb 13. Epub 2019 Feb 13.

Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.

Background: Disturbances in iron regulation have been described in diverse chronic liver diseases other than hereditary haemochromatosis, and iron toxicity may worsen liver injury and outcome.

Aims: To describe manifestations and consequences of iron dysregulation in chronic liver diseases apart from hereditary haemochromatosis and to encourage investigations that clarify pathogenic mechanisms, define risk thresholds for iron toxicity, and direct management METHODS: English abstracts were identified in PubMed by multiple search terms. Full length articles were selected for review, and secondary and tertiary bibliographies were developed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15173DOI Listing
February 2019
1 Read

[Acute decompensation (AD) of advanced chronic liver disease (ACLD) and hepatitis E virus (HEV) infection as the trigger].

Klin Mikrobiol Infekc Lek 2018 Sep;24(3):82-87

Division Hepatology, gastroenterology and liver transplantation of Department Internal medicine II, Faculty of Medicine, Slovak Medical University, FD Roosevelt Hospital, Banska Bystrica; Slovakia, e-mail:

Introduction: HEV infection is perceived as the cause of acute hepatitis in endemic areas. In addition, it may also manifest as a possible trigger of AD or acute-on-chronic liver failure (ACLF).

Objectives: To determine the prevalence of HEV infection as a trigger of AD/ACLF in patients admitted for decompensated ACLD (dACLD). Read More

View Article

Download full-text PDF

Source
September 2018
2 Reads

Bone Health in Patients With Liver Diseases.

J Clin Densitom 2019 Jan 18. Epub 2019 Jan 18.

Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA USA. Electronic address:

Osteoporosis is the most common bone disease in chronic liver disease (CLD) resulting in frequent fractures and leading to significant morbidity in this population. In addition to patients with cirrhosis and chronic cholestasis, patients with CLD from other etiologies may be affected in the absence of cirrhosis. The mechanism of osteoporosis in CLD varies according to etiology, but in cirrhosis and cholestatic liver disease it is driven primarily by decreased bone formation, which differs from the increased bone resorption seen in postmenopausal osteoporosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jocd.2019.01.004DOI Listing
January 2019
1 Read

Impact of a Multidisciplinary Team on Alcohol Recidivism and Survival After Liver Transplant for Alcoholic Disease.

Transplant Proc 2019 Jan - Feb;51(1):187-189. Epub 2018 Jun 30.

Hepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University of Modena and Reggio Emilia, Modena, Italy. Electronic address:

Background: Alcohol use disorders have a prevalence of 10% among the population of the United States and Europe and are one of the most frequent causes of liver cirrhosis in the Western world. Currently, alcohol-related liver cirrhosis represents one of the most frequent indications to liver transplant (LT), both as independent cause or associated with hepatitis C virus or hepatitis B virus infections. Starting from 2014, a multidisciplinary team involving surgeons, gastroenterologists, clinical toxicologists, psychiatrists, and psychologists was developed within the Modena Liver Transplant Center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2018.02.212DOI Listing
June 2018
1 Read

Autophagy in liver diseases: Time for translation?

J Hepatol 2019 Jan 31. Epub 2019 Jan 31.

Inserm UMR-1149, Centre de Recherche sur l'Inflammation, 75018 Paris, France; Sorbonne Paris Cité, Laboratoire d'Excellence Inflamex, Faculté de Médecine, Site Xavier Bichat, Université Paris Diderot, Paris, France. Electronic address:

Autophagy is a self-eating catabolic pathway that contributes to liver homeostasis through its role on energy balance and in the quality control of the cytoplasm, by removing misfolded proteins, damaged organelles and lipid droplets. Autophagy not only regulates hepatocyte functions but also impact on non-parenchymal cells such as endothelial cells, macrophages and hepatic stellate cells. Deregulation of autophagy has been linked to many liver diseases and its modulation is now recognized as a potential new therapeutic strategy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.01.026DOI Listing
January 2019
1 Read

The non-transcriptional activity of IRF3 modulates hepatic immune cell populations in acute on chronic ethanol administration in mice.

J Hepatol 2019 Jan 30. Epub 2019 Jan 30.

Departments of Inflammation and Immunity, Case Western Reserve University, Cleveland, Ohio, United States; Gastroenterology and Hepatology, Cleveland Clinic, Case Western Reserve University, Cleveland, Ohio, United States; Department of Molecular Medicine, Case Western Reserve University, Cleveland, Ohio, United States. Electronic address:

Background & Aims: Interferon regulatory factor 3 (IRF3) is a transcription factor mediating anti-viral responses, yet recent evidence indicates that IRF3 also has critical non-transcriptional functions, including activating RIG-I-like receptors-induced IRF-3-mediated pathway of apoptosis (RIPA) and restricting activity of NFκB. Using a novel murine model expressing only non-transcriptional IRF3 activity (Irf3), we tested the hypothesis that non-transcriptional functions of IRF3 modulate innate immune responses in the Gao-binge (acute on chronic) model of alcohol-related liver disease.

Methods: C57BL/6, Irf3 and Irf3 were exposed to Gao-binge ethanol-induced liver injury. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278193006
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2019.01.021DOI Listing
January 2019
4 Reads

Alcohol-related Liver Disease is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide.

Clin Gastroenterol Hepatol 2019 Jan 29. Epub 2019 Jan 29.

Division of Gastroenterology & Hepatology, Departments of Medicine and Nutrition, University of North Carolina at Chapel Hill, NC; Division of Gastroenterology, Hepatology, and Nutrition, Deparment of Medicine, Center for Liver Diseases, Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, PA. Electronic address:

Background & Aims: Despite recent advances in treatment of viral hepatitis, liver-related mortality is high, possibly due to the large burden of advanced alcohol-related liver disease (ALD). We investigated whether patients with ALD are initially seen at later stages of disease development than patients with hepatitis C virus (HCV) infection or other etiologies.

Methods: We performed a cross-sectional study of 3453 consecutive patients with either early or advanced liver disease (1699 patients with early and 1754 with advanced liver disease) seen at 17 tertiary care liver or gastrointestinal units worldwide, from August 2015 through March 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cgh.2019.01.026DOI Listing
January 2019
5 Reads

Non-uremic calciphylaxis associated with alcoholic hepatitis: A case report.

World J Hepatol 2019 Jan;11(1):127-132

Department of Dermatology, Cleveland Clinic, Cleveland 44195, OH, United States.

Background: Calciphylaxis is a form of vascular calcification more commonly associated with renal disease. While the exact mechanism of calciphylaxis is poorly understood, most cases are due to end stage kidney disease. However, it can also be found in patients without kidney disease and in such cases is termed non-uremic calciphylaxis for which have multiple proposed etiologies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4254/wjh.v11.i1.127DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354123PMC
January 2019
1 Read

Clinical factors associated with hepatitis B screening and vaccination in high-risk adults.

World J Hepatol 2019 Jan;11(1):86-98

Department of Medicine, Division of Gastroenterology, New York University Langone Health, New York, NY 10016, United States.

Background: Hepatitis B virus is a viral infection that can lead to acute and/or chronic liver disease, and hepatocellular carcinoma (HCC). Hepatitis B vaccination is 95% effective in preventing infection and the development of chronic liver disease and HCC due to hepatitis B. In 2011, the Centers for Disease Control updated their guidelines recommending that adults at high-risk for hepatitis B infection be vaccinated against hepatitis B including those with diabetes mellitus (DM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4254/wjh.v11.i1.86DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354120PMC
January 2019
1 Read

Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review.

World J Hepatol 2019 Jan;11(1):1-18

Division of Gastroenterology and Hepatology, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH 44109, the United States.

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, which in turns accounts for the sixth most common cancer worldwide. Despite being the 6 most common cancer it is the second leading cause of cancer related deaths. HCC typically arises in the background of cirrhosis, however, about 20% of cases can develop in a non-cirrhotic liver. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4254/wjh.v11.i1.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354117PMC
January 2019
1 Read

Serum lincRNA-p21 expression in primary liver diseases and liver metastatic diseases.

Pathol Res Pract 2019 Jan 14. Epub 2019 Jan 14.

Department of Clinical Laboratory, The Second Hospital, Shandong University, Jinan, Shandong, China. Electronic address:

Background: LincRNA-p21 is involved in the initiation and progression of many human diseases. We aimed to investigate the expression of LincRNA-p21 in different types of liver diseases.

Methods: Serum from patients with primary liver diseases (chronic HBV or HCV infection, hepatitis B virus-related cirrhosis, hepatitis B virus-related HCC, non-HBV/HCV-related HCC, alcoholic liver disease) and HBV negative liver metastatic cancer and control healthy individuals was collected and serum lincRNA-p21 levels were determined by RT-qPCR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2019.01.014DOI Listing
January 2019
1 Read
1.562 Impact Factor

Superinfection of hepatitis E as a factor in the development of acute hepatic encephalopathy on the background of HBV-cirrhosis of the liver.

Ter Arkh 2018 Feb;90(2):102-104

Kirov Infectious Clinical Hospital, Kirov, Russia.

The article presents an analysis of the clinical case of superinfection of autochthonous acute hepatitis E against the background of HBV-cirrhosis of the liver. HEV infection was diagnosed in a 39 year old man who did not travel outside the region and the country for a long time and used unboiled water. The peculiarity of the disease in the non-endemic region was: a severe course of hepatitis E against the background of HBV etiology, with the development of the clinic for acute hepatic insufficiency and encephalopathy, the presence of severe cytolysis syndrome, cholestasis, hepatic-cell insufficiency and prolonged convalescence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/terarkh2018902102-104DOI Listing
February 2018
2 Reads

Liver Transplantation in France.

Liver Transpl 2019 Jan 29. Epub 2019 Jan 29.

University Paris Diderot, Paris, France.

In France, the main indications for liver transplantation are hepatocellular carcinoma (HCC) and alcoholic cirrhosis. The number of candidates for decompensated hepatitis C virus (HCV)-related cirrhosis has markedly decreased since the advent of direct antiviral agents. Non-alcoholic steatohepatitis represents a lower proportion of candidates as compared to the United States. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/lt.25419DOI Listing
January 2019
2 Reads

Adiposity in relation to risks of fatty liver, cirrhosis and liver cancer: a prospective study of 0.5 million Chinese adults.

Sci Rep 2019 Jan 28;9(1):785. Epub 2019 Jan 28.

Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Adiposity is an increasing public health problem in China. We aimed to examine the associations of adiposity with non-alcoholic fatty liver disease (NAFLD) and other chronic liver diseases in Chinese adults. The prospective China Kadoorie Biobank recruited 512,891 adults aged 30-79 years from 10 areas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-36460-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349919PMC
January 2019
1 Read

New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance.

Authors:
Michael Karin

Precis Clin Med 2018 Jun 4;1(1):21-28. Epub 2018 Jun 4.

Laboratory of Gene Regulation and Signal Transduction, UC San Diego School of Medicine, Department of Pharmacology, 9500 Gilman Drive, La Jolla, CA, USA.

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. HCC initiates as a consequence of chronic liver damage and inflammation caused by hepatitis B and C virus infections, excessive alcohol consumption, or non-alcoholic fatty liver disease (NAFLD). Until recently, no effective treatments for advanced HCC were available and the 5-year survival rate had remained below 8% for many years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/pcmedi/pby005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333043PMC

Chronic hepatitis B and metabolic risk factors: A call for rigorous longitudinal studies.

Authors:
Wai-Kay Seto

World J Gastroenterol 2019 Jan;25(3):282-286

Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hong Kong, China.

Long-term nucleos(t)ide analogue therapy in chronic hepatitis B virus (HBV) infection is effective in suppressing viral replication and reducing liver-related complications. However, HBV-related liver events can still occur in different patient sub-groups. There is emerging evidence that, similar to chronic hepatitis C virus infection, metabolic risk factors may play a role in the disease process of chronic HBV. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v25.i3.282DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343097PMC
January 2019
1 Read

Anti-fibrotic activity of and paramylon in a mouse model of non-alcoholic steatohepatitis.

Food Sci Nutr 2019 Jan 8;7(1):139-147. Epub 2018 Nov 8.

Center for Research and Development of Bioresources Osaka Prefecture University Osaka Japan.

Progression to non-alcoholic steatohepatitis (NASH) manifests as hepatitis, fibrosis, and sometimes carcinoma, resulting in liver failure. Various clinical trials have indicated that several pharmacological agents, including angiotensin II receptor blockers (ARBs) or farnesoid X receptor (FXR) agonists, are effective in NASH treatment. In addition, functional foods are expected to be important alternatives for treating or preventing NASH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/fsn3.828DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341149PMC
January 2019
1 Read

Among Medicare Patients With Hepatocellular Carcinoma, Non-alcoholic Fatty Liver Disease is the Most Common Etiology and Cause of Mortality.

J Clin Gastroenterol 2019 Jan 21. Epub 2019 Jan 21.

Department of Medicine and Center For Liver Disease, Inova Fairfax Hospital.

Goals: The main purpose of this study was to assess the recent trends in mortality and health care utilization of hepatocellular carcinoma (HCC) among Medicare population in the United States.

Background: The incidence of HCC is increasing in the United States.

Materials And Methods: Data were obtained for a sample of Medicare beneficiary from 2005 to 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MCG.0000000000001172DOI Listing
January 2019
1 Read

Novel Ultrasonographic Fatty Liver Indicator Can Predict Hepatitis in Children With Non-alcoholic Fatty Liver Disease.

Front Pediatr 2018 8;6:416. Epub 2019 Jan 8.

Department of Pediatrics, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.

Childhood non-alcoholic fatty liver disease (NAFLD) is a public health issue worldwide. To date, liver biopsy remains the gold standard for diagnosing the severity of NAFLD. However, this invasive procedure might contribute to complications. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fped.2018.00416/
Publisher Site
http://dx.doi.org/10.3389/fped.2018.00416DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331417PMC
January 2019
10 Reads

The Role of Nrf2 in Liver Disease: Novel Molecular Mechanisms and Therapeutic Approaches.

Front Pharmacol 2018 8;9:1428. Epub 2019 Jan 8.

Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Oxidative stress and inflammation are the most important pathogenic events in the development and progression of liver diseases. Nuclear erythroid 2-related factor 2 (Nrf2) is the master regulator of the cellular protection induction of anti-inflammatory, antioxidant, and cyto-protective genes expression. Multiple studies have shown that activation or suppression of this transcriptional factor significantly affect progression of liver diseases. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fphar.2018.01428
Publisher Site
http://dx.doi.org/10.3389/fphar.2018.01428DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331455PMC
January 2019
4 Reads

National Trends and Long-term Outcomes of Liver Transplant for Alcohol-Associated Liver Disease in the United States.

JAMA Intern Med 2019 Jan 22. Epub 2019 Jan 22.

Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco.

Importance: Alcohol-associated liver disease (ALD) has emerged as the most common indication for liver transplant in the United States, but data on the reasons for this increase and long-term post-liver transplant outcomes among liver transplant recipients are sparse.

Objective: To characterize trends and long-term outcomes of liver transplant for ALD in the United States between 2002 and 2016.

Design, Setting, And Participants: This multicenter, prospective, national cohort study used data from the United Network for Organ Sharing database to evaluate all liver transplants performed in the United States between January 1, 2002, and December 31, 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamainternmed.2018.6536DOI Listing
January 2019
1 Read

Efficacy of g-csf in the management of steroid-nonresponsive severe alcoholic hepatitis: a double-blind randomized controlled trial.

Hepatology 2019 Jan 21. Epub 2019 Jan 21.

Department of Hepatology, Institute of Liver & Biliary Sciences, New Delhi, India.

Background And Aims: Severe alcoholic hepatitis (SAH) is often a progressive disease with high mortality and limited steroid responsiveness. Management options of steroid nonresponsive SAH (day 7 Lille-score>0.45) are limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30516DOI Listing
January 2019
1 Read
11.055 Impact Factor

Liver transplantation for alcoholic hepatitis.

J Hepatol 2019 Feb;70(2):328-334

Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, Madison WI, USA.

While liver transplantation (LT) has become a standard therapy for life-threatening alcohol related cirrhosis, LT as a treatment for severe alcoholic hepatitis (AH) has remained a taboo owing to concerns about the limited organ supply and the risk that the AH liver recipient will return to harmful drinking. The adoption of a 6-month abstinence requirement (the so-called '6-month rule') by many centres made AH a contraindication to LT. Given the high short-term mortality of severe AH, the lack of effective medical therapies and an increasing recognition that the 6-month rule unfairly excluded otherwise favourable candidates, a seminal European pilot study of LT for AH was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.11.007DOI Listing
February 2019
2 Reads

Acute-on-chronic liver failure in patients with alcohol-related liver disease.

J Hepatol 2019 Feb;70(2):319-327

The EASL-CLIF Consortium, European Foundation-CLIF, Barcelona, Spain; Liver Failure Group, Insitute for Liver and Digestive Health, University College London, London, UK.

The spectrum of alcohol-related liver diseases (ALD) includes steatosis, steatohepatitis, progressive liver fibrosis, and cirrhosis. Acute-on-chronic liver failure (ACLF) is a recently defined entity that occurs in patients with chronic liver diseases and is characterised by acute decompensation, organ failures and a high risk of short-term mortality. Active alcohol consumption, alcoholic hepatitis and bacterial infections are the most frequent events precipitating the development of ACLF in the context of ALD (ALD-ACLF). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278183262
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2018.12.008DOI Listing
February 2019
5 Reads

Endpoints and patient stratification in clinical trials for alcoholic hepatitis.

J Hepatol 2019 Feb;70(2):314-318

Digestive Diseases Division, Department of Surgery & Cancer, Imperial College, London W2 1NY, United Kingdom. Electronic address:

In some areas of medicine the clinical development pathway through phase II and III clinical trials has been well mapped out and refined through extensive experience. In contrast, a number of key questions remain unanswered in the development of novel therapeutics for alcoholic hepatitis. The use of mortality as an endpoint in phase II clinical trials will potentially restrict the appeal of this therapeutic area for pharmaceutical companies, as the number of patients required for adequately powered clinical trials becomes impractical. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.11.005DOI Listing
February 2019
1 Read

Current trials and novel therapeutic targets for alcoholic hepatitis.

J Hepatol 2019 Feb;70(2):305-313

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

Alcoholic hepatitis is a clinical syndrome in which patients present with acute-on-chronic liver failure and a high risk of short-term mortality. The current treatment of alcoholic hepatitis is suboptimal. Results recently published from the STOPAH study have improved our understanding of how best to design clinical trials for this condition. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278183251
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2018.10.026DOI Listing
February 2019
4 Reads

Microbiome as a therapeutic target in alcohol-related liver disease.

J Hepatol 2019 Feb;70(2):260-272

Department of Medicine, University of California San Diego, La Jolla, CA, USA; Department of Medicine, VA San Diego Healthcare System, San Diego, CA, USA. Electronic address:

Alcohol-related liver disease is associated with significant changes in gut microbial composition. The transmissibility of ethanol-induced liver disease has been demonstrated using faecal microbiota transfer in preclinical models. This technique has also led to improved survival in patients with severe alcoholic hepatitis, suggesting that changes in the composition and function of the gut microbiota are causatively linked to alcohol-related liver disease. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278183250
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2018.10.019DOI Listing
February 2019
4 Reads

Inflammatory pathways in alcoholic steatohepatitis.

J Hepatol 2019 Feb;70(2):249-259

Southern California Research Center for ALPD and Cirrhosis, Department of Pathology, University of Southern California, Greater Los Angeles VA Healthcare System, Los Angeles, CA, United States. Electronic address:

Inflammatory processes are primary contributors to the development and progression of alcoholic steatohepatitis (ASH), with severe alcoholic hepatitis characterised by non-resolving inflammation. Inflammation in the progression of ASH is a complex response to microbial dysbiosis, loss of barrier integrity in the intestine, hepatocellular stress and death, as well as inter-organ crosstalk. Herein, we review the roles of multiple cell types that are involved in inflammation in ASH, including resident macrophages and infiltrating monocytes, as well as other cell types in the innate and adaptive immune system. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278183250
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2018.10.023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361545PMC
February 2019
7 Reads

Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature.

Int J Mol Sci 2019 Jan 17;20(2). Epub 2019 Jan 17.

Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.

The rapid scientific interest in gut microbiota (GM) has coincided with a global increase in the prevalence of infectious and non-infectivous liver diseases. GM, which is also called "the new virtual metabolic organ", makes axis with a number of extraintestinal organs, such as kidneys, brain, cardiovascular, and the bone system. The gut-liver axis has attracted greater attention in recent years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20020395DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358912PMC
January 2019
2 Reads

[Prevalence and clinical features of non-alcoholic steatohepatitis in a hypertensive population].

Hipertens Riesgo Vasc 2019 Jan 14. Epub 2019 Jan 14.

Teoría de la Señal y las Comunicaciones y Sistemas Telemáticos y Computación, Universidad Rey Juan Carlos, Móstoles, Madrid, España.

Objective: Non-alcoholic fatty liver is a chronic liver disease in which fat is deposited in the liver, causing an inflammation called non-alcoholic steatohepatitis (NASH), and fibrosis. NASH is associated with metabolic syndrome (MS) and other cardiovascular risk factors. The aim of this study was to analyse the epidemiological features of NASH within a hypertensive population, with a high prevalence of MS, and to determine the features related to NASH. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18891837183009
Publisher Site
http://dx.doi.org/10.1016/j.hipert.2018.10.001DOI Listing
January 2019
6 Reads

Treatment retention in a specialized alcohol programme after an episode of alcoholic hepatitis: Impact on alcohol relapse.

J Psychosom Res 2019 Jan 28;116:75-82. Epub 2018 Nov 28.

Grup Recerca Addicions Clínic (GRAC-GRE), Department of Psychiatry, Clinical Institute of Neuroscience, Hospital Clínic i Universitari de Barcelona, Universitat de Barcelona, Villarroel, 170, 08036 Barcelona, Catalonia, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Rosselló, 149, 08036 Barcelona, Catalonia, Spain; Red de Trastornos Adictivos, RETICS, C/ Sinesio Delgado, 4, 28029 Madrid, Spain.

Aims: Alcoholic hepatitis (AH) is a life-threatening complication of alcohol use disorder (AUD). Alcohol abstinence is the main predictor of the long-term prognosis of AH. It is unknown whether AUD treatment retention (TR) after an AH episode impacts alcohol relapse and mortality or what baseline factors influence TR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpsychores.2018.11.020DOI Listing
January 2019
2 Reads

Extracellular Vesicles in Liver Diseases: Diagnostic, Prognostic, and Therapeutic Application.

Semin Liver Dis 2019 Feb 17;39(1):70-77. Epub 2019 Jan 17.

Department of General, Visceral and Thoracic Surgery, German Armed Forces Central Hospital, Koblenz, Germany.

Extracellular vesicles, comprising exosomes, microvesicles, and apoptotic bodies, represent an emerging field in disease diagnostics and prognosis. They can be isolated from peripheral blood of patients as well as from other body fluids and can therefore be considered a minimally invasive liquid biopsy screening tool. Especially their surface antigen composition can reveal information about disease backgrounds. Read More

View Article

Download full-text PDF

Source
http://www.thieme-connect.de/DOI/DOI?10.1055/s-0038-1676122
Publisher Site
http://dx.doi.org/10.1055/s-0038-1676122DOI Listing
February 2019
6 Reads

Outcome and safety of targeted liver biopsies for indeterminate lesions in patients with chronic liver disease: A single centre experience.

J Med Imaging Radiat Oncol 2019 Jan 16. Epub 2019 Jan 16.

Department of Radiology, Austin Hospital, Melbourne, Victoria, Australia.

Introduction: To evaluate the histopathological and safety outcomes of indeterminate lesions in patients at high risk for developing hepatocellular carcinoma (HCC) who underwent ultrasound-guided biopsies.

Methods: Ultrasound-guided targeted liver biopsies for indeterminate lesions performed in a 10-year period at our institution were reviewed retrospectively for lesion characteristics, biopsy techniques, histopathological results and post procedural complications.

Results: A total of 172 biopsies were performed in 152 patients. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/1754-9485.12856
Publisher Site
http://dx.doi.org/10.1111/1754-9485.12856DOI Listing
January 2019
6 Reads

Alcohol, liver disease and the gut microbiota.

Authors:
Jasmohan S Bajaj

Nat Rev Gastroenterol Hepatol 2019 Jan 14. Epub 2019 Jan 14.

Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA, USA.

Alcoholic liver disease, which ranges from mild disease to alcoholic hepatitis and cirrhosis, is a leading cause of morbidity and mortality worldwide. Alcohol intake can lead to changes in gut microbiota composition, even before liver disease development. These alterations worsen with advancing disease and could be complicit in disease progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41575-018-0099-1DOI Listing
January 2019
6 Reads

[The role of Cytochrom P4502E1 in Alcoholic Liver Disease and alcohol mediated carcinogenesis].

Z Gastroenterol 2019 Jan 14;57(1):37-45. Epub 2019 Jan 14.

Department of Medicine and Liver Diseases, Salem Medical Center, University of Heidelberg, Germany.

Various factors are involved in the pathogenesis of alcoholic liver disease (ALD) and ethanol-mediated carcinogenesis. In addition to genetic, epigenetic and immunologic mechanisms, acetaldehyde-associated toxicity, oxidative stress as well as cytokine-mediated inflammation are of major importance. Oxidative stress, with the generation of reactive oxygen species (ROS), develops either in inflammation (alcoholic hepatitis) or during oxidation of ethanol via cytochrome P4502E1 (CYP2E1). Read More

View Article

Download full-text PDF

Source
http://www.thieme-connect.de/DOI/DOI?10.1055/a-0784-8815
Publisher Site
http://dx.doi.org/10.1055/a-0784-8815DOI Listing
January 2019
4 Reads

A practical clinical approach to liver fibrosis.

Singapore Med J 2018 12;59(12):628-633

Department of Gastroenterology and Hepatology, Changi General Hospital, Singapore.

Liver fibrosis is a slow, insidious process involving accumulation of extracellular matrix protein in the liver. The stage of liver fibrosis in chronic liver disease (CLD) determines overall morbidity and mortality; the higher the stage, the worse the prognosis. Noninvasive composite scores can be used to determine whether patients with CLD have significant or advanced fibrosis. Read More

View Article

Download full-text PDF

Source
http://www.smj.org.sg/article/practical-clinical-approach-li
Publisher Site
http://dx.doi.org/10.11622/smedj.2018145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301869PMC
December 2018
5 Reads
0.634 Impact Factor

Liver Resection for Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: a Multicenter Propensity Matching Analysis with HBV-HCC.

J Gastrointest Surg 2019 Jan 7. Epub 2019 Jan 7.

Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, No. 225, Changhai Road, Shanghai, 200438, China.

Background: The incidence of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) is increasing worldwide. Higher perioperative risks may be anticipated due to underlying steatohepatitis, while long-term outcomes after liver resection are unknown. We sought to investigate outcomes after liver resection for NAFLD-HCC versus hepatitis B virus (HBV)-HCC using propensity score matching (PSM). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11605-018-04071-2
Publisher Site
http://dx.doi.org/10.1007/s11605-018-04071-2DOI Listing
January 2019
5 Reads

Incidence and Mortality of Acute on Chronic Liver Failure using Two Definitions in Patients with Compensated Cirrhosis.

Hepatology 2019 Jan 7. Epub 2019 Jan 7.

Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

Background And Aims: The term acute on chronic liver failure (ACLF) intends to identify chronic liver disease patients who develop rapid deterioration of liver function and high short-term mortality after an acute insult. The two prominent definitions (European Association for the Study of the Liver [EASL] and Asian Pacific Association for the Study of the Liver [APASL]) differ, and existing literature applies to narrow patient groups. We sought to compare ACLF incidence and mortality among a diverse cohort of compensated cirrhotic patients, using both definitions. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hep.30494
Publisher Site
http://dx.doi.org/10.1002/hep.30494DOI Listing
January 2019
9 Reads

Haemostatic Profiles are Similar across All Aetiologies of Cirrhosis.

Thromb Haemost 2019 Feb 4;119(2):246-253. Epub 2019 Jan 4.

Surgical Research Laboratory and Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Background And Aim:  Patients with cirrhosis may acquire profound changes in haemostasis. Although haemostatic changes in cirrhosis have been extensively studied, most studies were performed in groups of patients with mixed aetiology. As thrombotic events appear more common in some aetiologies of disease, notably non-alcoholic steatohepatitis (NASH) and cholestatic disease, we hypothesized that haemostatic changes might be different across aetiologies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0038-1676954DOI Listing
February 2019
2 Reads